Bomedemstat extension trial tests Long-Term safety for blood cancer patients
NCT ID NCT05223920
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looks at the long-term safety of bomedemstat, an oral drug, in 81 people with myeloproliferative neoplasms (MPNs) like essential thrombocythemia and primary myelofibrosis. Participants had already taken bomedemstat in a prior study. Researchers tracked side effects, spleen size, and platelet counts to see if the drug remains safe and effective over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bomedemstat (oral capsule)
What this could lead to
If successful, this study could show that bomedemstat is safe and effective for long-term control of myeloproliferative neoplasms, offering a new treatment option.
What could go wrong
This is a small, early-phase extension study with no placebo group, so results may not prove long-term benefit. Side effects are possible, and the drug may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azienda Ospedaliera SS. Antonio
Alessandria, 15121, Italy
-
Azienda Ospedaliero Universitaria di Bologna
Pavia, 27100, Italy
-
Azienda Ospedaliero-Universitaria Careggi - S.O.D. Ematologia (CRIMM)
Florence, 50134, Italy
-
Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
Gold Coast Hospital and Health Service
Southport, Queensland, 4215, Australia
-
Guy's and Saint Thomas' NHS Foundation Trus
London, SE1 9RT, United Kingdom
-
Middlemore Clinical Trials
Papatoetoe, Aukland, 2025, New Zealand
-
Ospedale di Circolo-a Fondazione Macchi
Varese, VA, 2100, Italy
-
Queen Mary Hospital
Hong Kong, Hong Kong
-
Royal Adelaide Hospital
Adelaide, South Australia, 5000, Australia
-
Royal North Shore Hospital
Saint Leonards, New South Wales, 2065, Australia
-
Royal Prince Alfred Hospital
Camperdown, New South Wales, 2050, Australia
-
UMPC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
Universittsklinikum Essen
Essen, 45147, Germany
-
University College London Hospitals NHS Foundation Trust
London, NW1 12G, United Kingdom
-
University of Miami Leonard M. Miller
Miami, Florida, 33136, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
Waitemata District Health Board
Takapuna, Aukland, 0622, New Zealand